Hartmann M - Search Results

1

A Thorough QT Study of Teduglutide in Healthy Subjects.

Hartmann M, Timmer W, Schultz A, Nave R, Luehmann R, Krause S, Lahu G, Scholpp J. Hartmann M, et al. Clin Pharmacol Drug Dev. 2012 Apr;1(2):57-66. doi: 10.1177/2160763X12438745. Clin Pharmacol Drug Dev. 2012. PMID: 27121220

2

Pharmacokinetics of teduglutide in subjects with renal impairment.

Nave R, Halabi A, Herzog R, Schaffer P, Diefenbach J, Krause S, Berghöfer P, Lahu G, Hartmann M. Nave R, et al. Among authors: hartmann m. Eur J Clin Pharmacol. 2013 May;69(5):1149-55. doi: 10.1007/s00228-012-1455-7. Epub 2012 Nov 28. Eur J Clin Pharmacol. 2013. PMID: 23187965 Clinical Trial.

3

Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.

Bethke TD, Hartmann M, Hünnemeyer A, Lahu G, Gleiter CH. Bethke TD, et al. Among authors: hartmann m. Int J Clin Pharmacol Ther. 2011 Aug;49(8):491-9. doi: 10.5414/cp201556. Int J Clin Pharmacol Ther. 2011. PMID: 21781649 Clinical Trial.

4

Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man.

Ehrlich A, Fuder H, Hartmann M, Wieckhorst G, Timmer W, Huber R, Birkel M, Bliesath H, Steinijans VW, Wurst W, Lücker PW. Ehrlich A, et al. Among authors: hartmann m. Eur J Clin Pharmacol. 1996;51(3-4):277-81. doi: 10.1007/s002280050198. Eur J Clin Pharmacol. 1996. PMID: 9010699

5

Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole.

Hartmann M, Ehrlich A, Fuder H, Lühmann R, Emeklibas S, Timmer W, Wurst W, Lücker PW. Hartmann M, et al. Aliment Pharmacol Ther. 1998 Oct;12(10):1027-32. doi: 10.1046/j.1365-2036.1998.00406.x. Aliment Pharmacol Ther. 1998. PMID: 9798809 Clinical Trial.

6

Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers.

Koch HJ, Hartmann M, Bliesath H, Huber R, Steinijans VW, Mascher H, Wurst W. Koch HJ, et al. Among authors: hartmann m. Int J Clin Pharmacol Ther. 1996 Oct;34(10):420-3. Int J Clin Pharmacol Ther. 1996. PMID: 8897078 Clinical Trial.

7

Pantoprazole lacks induction of CYP1A2 activity in man.

Hartmann M, Zech K, Bliesath H, Steinijans VW, Koch H, Wurst W, Mascher H. Hartmann M, et al. Int J Clin Pharmacol Ther. 1999 Apr;37(4):159-64. Int J Clin Pharmacol Ther. 1999. PMID: 10235417 Clinical Trial.

8

Pantoprazole does not interact with the pharmacokinetics of carbamazepine.

Huber R, Bliesath H, Hartmann M, Steinijans VW, Koch H, Mascher H, Wurst W. Huber R, et al. Among authors: hartmann m. Int J Clin Pharmacol Ther. 1998 Oct;36(10):521-4. Int J Clin Pharmacol Ther. 1998. PMID: 9799054 Clinical Trial.

9

Lack of interaction between pantoprazole and digoxin at therapeutic doses in man.

Hartmann M, Huber R, Bliesath H, Steinijans VW, Koch HJ, Wurst W, Kunz K. Hartmann M, et al. Int J Clin Pharmacol Ther. 1995 Sep;33(9):481-5. Int J Clin Pharmacol Ther. 1995. PMID: 8520804 Clinical Trial.

10

Lack of interaction between pantoprazole and digoxin at therapeutic doses in man.

Hartmann M, Huber R, Bliesath H, Steinijans VW, Koch HJ, Wurst W, Kunz K. Hartmann M, et al. Int J Clin Pharmacol Ther. 1996 May;34(1 Suppl):S67-71. Int J Clin Pharmacol Ther. 1996. PMID: 8793605 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,020 results

Search Page

Filters